A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
AstraZeneca
Timser SAPI de CV
Karolinska Institutet
City of Hope Medical Center
University of Oklahoma
Baylor Research Institute
Bio-Thera Solutions
City of Hope Medical Center
Women's Hospital School Of Medicine Zhejiang University
UNC Lineberger Comprehensive Cancer Center
Institut Bergonié
Peking University
National Cancer Institute (NCI)
National Institute of Cancerología
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
AGO Research GmbH
Vall d'Hebron Institute of Oncology
WellSpan Health
Pfizer
MetroHealth Medical Center
Centre Hospitalier Universitaire Vaudois
ImmunityBio, Inc.
Cordgenics, LLC
University of Pittsburgh
Astellas Pharma Inc
University of Pittsburgh
Sir Mortimer B. Davis - Jewish General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Travera Inc
Herning Hospital
University of Pittsburgh
Washington University School of Medicine
Nykode Therapeutics ASA
Brown University
GOG Foundation
University of California, San Diego
Assiut University
Genmab
University of Alabama at Birmingham
Beijing Kejing Biotechnology Co., Ltd.
Massachusetts General Hospital
Agenus Inc.
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Mainline Biosciences, Inc.
University of New Mexico
Roswell Park Cancer Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
QuantumLeap Healthcare Collaborative